PAVmed Inc. - Series Z Warrant (OQ:PAVMZ)

Business Focus: N/A

Get the company report for the most recent outlook updated daily

Jan 17, 2023 04:05 pm ET

PAVmed and Lucid Diagnostics Provide Strategic Business Update

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, and its majority-owned subsidiaries Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid” or “Lucid Diagnostics”), a commercial-stage cancer prevention diagnostics company, and Veris Health Inc. (“Veris”), a private digital health company focused on enhanced personalized cancer care, today provided a strategic business update, outlining near-term strategic priorities and resource reallocation. The companies will prioritize ne

Jan 11, 2023 08:00 am ET

PAVmed and Lucid Diagnostics to Provide Strategic Business Update

PAVmed Inc. (Nasdaq: PAVM, PAVMZ), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, and its majority-owned subsidiaries

Dec 22, 2022 08:25 am ET

PAVmed Partners with Novosound on Ultrasound Imaging Technology

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it has entered into a license option and joint research and development agreement with Novosound Ltd. (“Novosound”), a venture-backed technology

Dec 15, 2022 08:25 am ET

PAVmed Digital Health Subsidiary Veris Health Launches Veris Cancer Care Platform

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that its majority-owned digital health subsidiary Veris Health Inc. (“Veris”), has commercially launched its Veris Cancer Care Platform™ (“Veris CCP”)

Dec 08, 2022 08:25 am ET

Lucid Diagnostics Selected as Finalist for Medtech Company of the Year 2022 by Medical Device + Diagnostic Industry

Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid” or the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of

Dec 01, 2022 08:25 am ET

Lucid Diagnostics Presents Real-World EsoCheck Data at the American Association for Cancer Research

Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of

Nov 14, 2022 04:40 pm ET

Lucid Diagnostics Provides Business Update and Third Quarter 2022 Financial Results

Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid” or the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of

Nov 11, 2022 08:25 am ET

PAVmed to Participate in BTIG Digital Health Forum

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”, the “Company”), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, today announced that

Nov 10, 2022 08:25 am ET

Lucid Diagnostics to Participate in Canaccord Genuity’s MedTech, Diagnostics and Digital Health & Services Forum

Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”, the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of

Nov 09, 2022 08:25 am ET

Lucid Diagnostics Commences Production of EsoCheck Devices with High-Volume Manufacturer

Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”, the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of

Nov 03, 2022 08:25 am ET

PAVmed to Hold a Business Update Conference Call and Webcast on November 15, 2022

PAVmed Inc. (Nasdaq: PAVM, PAVMZ), a diversified commercial-stage medical device company today announced that the Company will host a business update conference call and webcast on Tuesday, November 15, 2022, at 4:30 PM EDT. During the call,

Nov 02, 2022 08:25 am ET

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 14, 2022

Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, a majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced that the Company will host a business update conference call and webcast on Monday, November 14, 2022, at 4:30 PM EDT. During the call,

Aug 30, 2022 08:25 am ET

PAVmed to Participate in the Lake Street 6th Annual Best Ideas Growth Conference and the A.G.P. Virtual MedTech Conference

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical device company operating in the medical device, diagnostics, and digital health sectors, today announced that Lishan Aklog, M.D., the Company’s Chairman and CEO, will participate in one-on-one investor meetings at Lake Street Capital Markets’

Aug 16, 2022 04:40 pm ET

PAVmed Provides Business Update and Preliminary Second Quarter 2022 Financial Results

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) and Veris Health Inc. (“Veris”

Aug 11, 2022 08:25 am ET

Lucid Diagnostics Launches Stage II Lucid Test Center Expansion in California, Texas, Florida, and Ohio

Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of

Aug 04, 2022 08:25 am ET

Newly Published American Gastroenterological Association Clinical Practice Update Supports Esophageal Precancer Screening Using Lucid Diagnostics’ EsoGuard® and EsoCheck® Technologies

Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of

Jul 19, 2022 08:25 am ET

PAVmed Chairman & CEO Lishan Aklog, M.D. Named to Savoy’s 2022 Most Influential Black Executives in Corporate America

Jul 18, 2022 08:25 am ET

Lucid Diagnostics to Participate in the Canaccord 42nd Annual Growth Conference and the 7th Annual Needham Med Tech & Diagnostics 1x1 Conference

Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of

May 13, 2022 08:25 am ET

PAVmed and Lucid Diagnostics Chairman & CEO Lishan Aklog, M.D. Named Top 50 Healthcare Technology CEO

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a diversified commercial-stage medical technology company, and its majority-owned subsidiary

Apr 28, 2022 04:05 pm ET

PAVmed Announces Procedural Update on its Settlement of a Previously Disclosed Class Action Lawsuit

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company, today announced a procedural update on its settlement of a previously disclosed class action lawsuit. As previously...

Apr 26, 2022 08:25 am ET

PAVmed to Hold a Business Update Conference Call on May 12, 2022

PAVmed Inc. (Nasdaq: PAVM, PAVMZ), a highly differentiated, multi-product, commercial-stage medical device company today announced that the Company will host a business update conference call on Thursday, May 12, 2022, at 4:30 PM EDT. During the call, Lishan Aklog, M.D., Chairman and Chief Executive Officer, will provide a busin

Mar 29, 2022 04:11 pm ET

PAVmed Provides Business Update and Preliminary Fourth Quarter and Full Year 2021 Financial Results

Mar 23, 2022 08:25 am ET

PAVmed Subsidiary Lucid Diagnostics Launches Next Phase of Lucid Test Centers

Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), a commercial-stage cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced that it has launched Lucid Test Centers in three new metropolitan areas—Seattle, Washington, Portland, Oregon, and Boise, Idaho. Patients in these cities with chronic heartburn, also known as gastroesophageal reflux disease (“GERD”), and an order from their own physician or from a telemedicine physician provided to them after self-referral, can now undergo a brief, non-inva

Mar 17, 2022 08:25 am ET

PAVmed Announces Successful First-in-Human Implantations of its PortIO™ Intraosseous Infusion System

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company, today announced that physicians at the Clinica Porto Azul in Barranquilla, Colombia successfully implanted the Company’s PortIO™ Intraosseous Infusion System in three patients—the first human implants of the device—as part of its IRB-approved first-in-human (FIH) clinical study of up to 40 patients. All patients have also undergone successful infusion of fluids consistent with the study protocol and the device’s intended use. No complications have occurred.

Mar 10, 2022 08:25 am ET

PAVmed Subsidiary Veris Health Launches World-Class Technology Advisory Board

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a diversified commercial-stage medical technology company today announced that its majority-owned digital health subsidiary Veris Health (“Veris”) has launched a world-class technology advisory board consisting of Silicon Valley luminaries with broad expertise in software development, hardware engineering, data and analytics, machine learning, and consumer engagement. Silicon Valley pioneer Rich Page, an early Apple alumnus who co-founded NeXT Computer with Steve Jobs, will serve as chair. The advisory board held its inaugural meeting

Mar 08, 2022 08:30 am ET

PAVmed to Hold a Business Update Conference Call on March 29, 2022

PAVmed Inc. (Nasdaq: PAVM, PAVMZ), a highly differentiated, multi-product, commercial-stage medical device company today announced that the companies will host a business update conference call on Tuesday, March 29, 2022, at 4:30 PM EDT. During the call, Lishan Aklog, M.D., Chairman, and Chief Executive Officer, will provide a b

Mar 07, 2022 08:30 am ET

Lucid Diagnostics to Hold a Business Update Conference Call on March 28, 2022

Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, a majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced that the companies will host a business update conference call on Monday, March 28, 2022, at 4:30 PM EDT. During the call, Lishan Aklog, M

Mar 04, 2022 08:25 am ET

Lucid Diagnostics to Participate in the LSI USA ’22 Emerging Medtech Summit

Mar 03, 2022 08:25 am ET

PAVmed Subsidiary Lucid Diagnostics Launches LucidDx Labs to Accommodate EsoGuard Testing Growth

Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced that a new, wholly owned subsidiary of Lucid, LucidDx Labs Inc. (“LucidDx Labs”) has acquired from ResearchDx, Inc. (“RDx”), a CLIA-certified, CAP-accredited clinical laboratory operator located in Irvine, CA, certain licenses and other related assets necessary for LucidDx Labs to operate its own new CLIA-certified, CAP-accredited clinical laboratory located in Lake Forest,

Feb 24, 2022 08:25 am ET

PAVmed Appoints Shaun O’Neil as Chief Operating Officer

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company and parent of cancer prevention company Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), today announced the appointment of Shaun O’Neil to serve as Executive Vice President and Chief Operating Officer, overseeing diverse corporate operations and commercial activities across the Company and its subsidiaries. Mr. O’Neil has served as PAVmed’s Chief Commercial Officer and Executive Vice President, Business Development since joining the Company in 2018. He will se

Feb 15, 2022 08:25 am ET

Evernorth Executive and Healthcare Services Industry Leader Joan Harvey Named to PAVmed Board of Directors

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company and parent of cancer prevention company Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), today announced the appointment of prominent healthcare services industry leader and president of Care Solutions for Evernorth, Joan Harvey, to its Board of Directors. Ms. Harvey will serve as a member of the Company’s Audit and Compensation Committees.

Feb 10, 2022 08:25 am ET

Lucid Diagnostics to Participate in a Fireside Chat at the BTIG MedTech Digital Health, Life Science, and Diagnostics Tools Conference

Jan 12, 2022 08:25 am ET

PAVmed and Lucid Diagnostics Welcome New Full-Time Investor Relations Team

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a diversified commercial-stage medical technology company, and its majority-owned subsidiary Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), a commercial-stage cancer prevention diagnostics company, today announced they have launched a new, full-time investor relations team to serve both companies.

Jan 06, 2022 08:30 am ET

Lucid Diagnostics to Participate in a Fireside Chat at the 24th Annual Needham Virtual Growth Conference

Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced that Lishan Aklog, Chairman and CEO, will participate in a Fireside Chat at the 24th Annual Needham Virtual Growth Conference on January 11, 2022, at 11:30 AM EST. The live presentation can be accessed on the “Investor Relations” section of Lucid Diagnostics’ website at

Dec 01, 2021 08:30 am ET

PAVmed Subsidiary Lucid Diagnostics Launches EsoGuard Telemedicine Program in Partnership with UpScriptHealth

Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced it has launched its EsoGuard Telemedicine Program in partnership with UpScriptHealth, a leading, nationwide, direct-to-consumer telemedicine company.

Nov 17, 2021 08:30 am ET

Lucid Diagnostics to Present at Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum

Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced that Dennis McGrath, Chief Financial Officer, will present a corporate update at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum on November 18, 2021, at 4:00 PM EST. For more information on the conference, visit

Nov 16, 2021 04:13 pm ET

PAVmed and Lucid Provide Business Update and Preliminary Third Quarter 2021 Financial Results

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, and its majority-owned subsidiary Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), a commercial-stage cancer prevention diagnostics company today provided a joint business update for the companies and discussed preliminary financial results for the six and nine months ended September 30, 2021.

Nov 11, 2021 08:30 am ET

PAVmed Subsidiary Lucid Diagnostics Launches Next Phase of Lucid Test Centers

Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced it has launched Lucid Test Centers in three new metropolitan areas—Denver, Salt Lake City, and Las Vegas. Patients in these cities with chronic heartburn, also known as gastroesophageal reflux disease (“GERD”), who are referred by their primary care physician (PCP) or who self-refer can now undergo a rapid, non-invasive, office-based test to detect esophageal precancer befo

Nov 03, 2021 08:30 am ET

PAVmed and Lucid to Hold Joint Business Update Conference Call on November 16, 2021

PAVmed Inc. (Nasdaq: PAVM, PAVMZ), a highly differentiated, multi-product, commercial-stage medical device company, and its major subsidiary Lucid Diagnostics Inc. (Nasdaq: LUCD), a cancer prevention medical diagnostics company today announced that the companies will host a joint business update conference call on Tuesday, November 16, 2021, at 4:30 PM EDT. During the call, Lishan Aklog, M.D., Chairman and Chief Executive Officer of the companies, will provide a business update including an overview of the Company’s near-term milestones and growth strategy. In addition, Dennis McGrath,

Oct 29, 2021 08:30 am ET

Veris Health Showcased in PAVmed Digital Health Virtual Investor Event

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, hosted a virtual investor event with several hundred participants on October 26, 2021. The event, Veris Heath: Bringing Digital Health to Cancer Care, focused on PAVmed’s digital health subsidiary Veris Health (“Veris”).

Oct 28, 2021 08:30 am ET

Lucid Diagnostics’ EsoGuard Esophageal DNA Test Wins “Diagnostics Innovation of the Year” Award

Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced its EsoGuard® Esophageal DNA Test has been selected as winner of the “Diagnostics Innovation of the Year” award in the inaugural awards program conducted by

Oct 25, 2021 08:30 am ET

PAVmed Digital Health Subsidiary Veris Health Appoints Sunny Webb as Chief Technology Officer

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, and its digital health subsidiary Veris Health (“Veris”) today announced the appointment of Silicon Valley technology executive Sunny Webb as Veris’ Chief Technology Officer and PAVmed’s VP, Data & Analytics.

Oct 21, 2021 12:59 pm ET

ADDING MULTIMEDIA Lucid Diagnostics Appoints Suman Verma MD, PhD as Chief Scientific Officer

Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced the appointment of highly accomplished molecular biologist Suman M. Verma, M.D., Ph.D. as Lucid’s Chief Scientific Officer and PAVmed’s VP, Molecular Diagnostics.

Oct 21, 2021 08:30 am ET

Lucid Diagnostics Appoints Suman Verma MD, PhD as Chief Scientific Officer

Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced the appointment of highly accomplished molecular biologist Suman M. Verma, M.D., Ph.D. as Lucid’s Chief Scientific Officer and PAVmed’s VP, Molecular Diagnostics.

Oct 18, 2021 06:09 pm ET

Lucid Diagnostics Announces Closing of Nasdaq Initial Public Offering

Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced the closing on October 18, 2021 of its initial public offering (the “Offering”) of 5,000,000 shares of common stock at a price to the public of $14.00 per share for total gross proceeds of $70,000,000 before deducting underwriting discounts and commissions and estimated offering expenses.

Oct 18, 2021 05:45 pm ET

Lucid Diagnostics Announces Closing of Nasdaq Initial Public Offering

Oct 13, 2021 10:15 pm ET

Lucid Diagnostics Announces Pricing of Initial Public Offering

Oct 13, 2021 09:28 pm ET

Lucid Diagnostics Announces Pricing of Initial Public Offering

Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price to the public of $14.00 per share. All of the shares are being offered by Lucid. The gross proceeds to Lucid from the offering, before deducting underwriting discounts, commissions and other offering expenses payable by Lucid, are expected to be $70,000,000. In addition, Lucid has granted the underwriters a 30

Oct 07, 2021 11:41 am ET

PAVmed Acquires EsophaCap Manufacturer CapNostics LLC

Oct 07, 2021 09:30 am ET

PAVmed Acquires EsophaCap Manufacturer CapNostics LLC

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced a wholly owned subsidiary of the Company has entered into a definitive membership interests purchase agreement with Martin Von Dyck, the sole member and owner of North Carolina-based CapNostics, LLC, which manufactures EsophaCap®—a U.S. FDA 510(k)-cleared and European CE Mark certified, non-endoscopic esophageal cell collection device which has been used in pre-commercial clinical research of esophageal precancer b

Sep 30, 2021 10:34 am ET

PAVmed to Host Digital Health Virtual Investor Event

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that on October 26, 2021, from 1 to 3 PM EDT, it will host a virtual investor event focused on its digital health subsidiary Veris Health (“Veris”) entitled Veris Heath: Bringing Digital Health to Cancer Care. Attendees may register for the event

Sep 21, 2021 09:30 am ET

PAVmed Subsidiary Veris Health Joins Microsoft for Startups Global Program and Engages Loka as Software Development Partner

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that its major subsidiary Veris Health Inc. (“Veris”) has been accepted into Microsoft for Startups, a global program from Microsoft dedicated to accelerating the trajectory of startups. The Company also announced that Veris has entered into a definitive services agreement with leading full-service Silicon Valley-based full-stack software development firm Loka Inc. (“Loka”) to build its remote digital healthcare platform.

Sep 07, 2021 10:04 am ET

PAVmed to Participate in September Investor and MedTech Conferences

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced the company’s management team will participate in the

Aug 12, 2021 04:14 pm ET

PAVmed Provides Business Update and Preliminary Second Quarter 2021 Financial Results

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today provided a business update for the Company and its major subsidiary, Lucid Diagnostics Inc. (“Lucid”), and discussed preliminary financial results for the three and six months ended June 30, 2021.

Aug 10, 2021 09:30 am ET

PAVmed Subsidiary Lucid Diagnostics Launches First Lucid Test Centers

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that its majority owned subsidiary Lucid Diagnostics Inc. (“Lucid”) has begun testing patients referred by primary care physicians (“PCPs”) at three Lucid Test Centers in the Phoenix metropolitan area. Patients with chronic heartburn, also known as gastroesophageal reflux disease (“GERD”), who are referred to the centers undergo a rapid non-invasive office procedure, performed by Lucid-employed clinical personnel, using Lucid

Aug 05, 2021 09:30 am ET

PAVmed to Present at the 41st Annual Canaccord Genuity Growth Conference

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer will present a corporate update at the 41st Annual Canaccord Genuity Growth Conference on August 11, 2021, at 5:00 PM EDT.

Aug 03, 2021 09:30 am ET

Global Industry Executive Aster Angagaw Joins PAVmed Subsidiary Lucid Diagnostics’ Board of Directors

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that prominent global industry executive Aster Angagaw has joined the Board of Directors of its majority owned subsidiary Lucid Diagnostics Inc. (“Lucid”). Ms. Angagaw will serve on the Company’s Audit and Nominating Committees.

Aug 02, 2021 12:31 pm ET

CORRECTING and REPLACING PAVmed to Hold Business Update Conference Call on August 12, 2021

First paragraph, first sentence of release should read: ...Thursday, August 12, 2021, at 4:30 PM EDT (instead of Monday, August 12, 2021, at 4:30 PM EDT).

Aug 02, 2021 09:30 am ET

PAVmed to Hold Business Update Conference Call on August 12, 2021

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced that the Company will host a business update conference call on Monday, August 12, 2021, at 4:30 PM EDT. During the call, Lishan Aklog, M.D., Chairman and Chief Executive Officer of the Company, will provide a business update including an overview of the Company’s near-term milestones and growth strategy. In addition, Dennis McGrath, the Company’s President and Chief Financial Officer, will discuss second quarter 2021 financial r

Jul 28, 2021 09:30 am ET

Stanley Lapidus, Founder and Former Chairman & CEO of Exact Sciences, Joins PAVmed Subsidiary Lucid Diagnostics as Vice Chairman of its Board of Directors

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that medical diagnostics pioneer Stanley N. Lapidus, founder and former Chairman and CEO of Exact Sciences (Nasdaq: EXAS), has joined its majority owned subsidiary Lucid Diagnostics Inc. (“Lucid”) as Vice Chairman of Lucid’s Board of Directors.

Jul 22, 2021 09:30 am ET

PAVmed Subsidiary Lucid Diagnostics Launches Strategic Partnership with Direct-to-Consumer Telemedicine Company UpScriptHealth

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that its major subsidiary Lucid Diagnostics Inc. (“Lucid”) has entered into a definitive agreement with UpScriptHealth (“UpScript”), a leading, nationwide, direct-to-consumer telemedicine company. Pursuant to the agreement, UpScript will support Lucid’s upcoming EsoGuard Telemedicine Program by providing a Lucid-branded web-based telemedicine platform for patients with chronic heartburn symptoms to request video evaluation by

Jun 14, 2021 09:30 am ET

Tim Baxter, Former CEO of Samsung Electronics North America and Global Technology Industry Leader, Joins PAVmed Board of Directors

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced the appointment of prominent global technology industry leader Tim Baxter, to its...

Jun 10, 2021 09:30 am ET

PAVmed Subsidiary Lucid Diagnostics Completes European CE Mark Certification of its EsoGuard Esophageal DNA Test

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced that its major subsidiary, Lucid Diagnostics Inc. (“Lucid”), has completed European IVDD CE Mark...

Jun 02, 2021 09:30 am ET

PAVmed Launches Digital Health Company Veris Health Inc.

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced the launch of a new subsidiary, digital health company Veris Health Inc. (“Veris”),...

May 26, 2021 09:30 am ET

PAVmed Subsidiary Lucid Diagnostics Receives CE Mark Certification for its EsoCheck® Esophageal Cell Collection Device

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, and its major subsidiary Lucid Diagnostics Inc. (“Lucid”), today announced that Lucid’s EsoCheck® Esophageal Cell...

May 25, 2021 09:30 am ET

PAVmed Receives European CE Mark Certification for its CarpX® Minimally Invasive Carpal Tunnel Device

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced that it has received CE Mark certification for its CarpX® minimally invasive carpal...

May 24, 2021 09:30 am ET

Data Presented at Digestive Disease Week 2021 Support Clinical Utility of PAVmed Subsidiary Lucid Diagnostics’ EsoCheck and EsoGuard Technologies

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, and its major subsidiary Lucid Diagnostics Inc. (“Lucid”), today announced that David M. Poppers, M.D. Ph.D.,...

May 17, 2021 04:00 pm ET

PAVmed Provides Business Update and First Quarter 2021 Financial Results

May 13, 2021 09:30 am ET

PAVmed Subsidiary Lucid Diagnostics Announces Upcoming Presentation at Digestive Disease Week 2021

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed” or the “Company”), a highly differentiated, multi-product, commercial-stage medical technology company, and its major subsidiary Lucid Diagnostics Inc. (“Lucid”), announced today that David Poppers, M.D....

May 06, 2021 09:30 am ET

PAVmed Subsidiary Lucid Diagnostics Expands Commercial Leadership Team

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed” or the “Company”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that its major subsidiary Lucid Diagnostics Inc. (“Lucid” or the “Company”) has...

May 03, 2021 09:30 am ET

PAVmed to Hold Business Update Conference Call on May 17, 2021

Apr 29, 2021 09:30 am ET

Dr. Jacque Sokolov Joins PAVmed Subsidiary Lucid Diagnostics’ Board of Directors

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that its major subsidiary Lucid Diagnostics Inc. (“Lucid” or the “Company”) has appointed nationally...

Apr 27, 2021 09:30 am ET

Global Industry Executive Debbie White Joins PAVmed Board of Directors

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced the appointment of prominent UK-based global industry executive, Debbie White, to...

Apr 15, 2021 09:30 am ET

PAVmed Chairman & CEO Lishan Aklog, M.D. named Top 50 Healthcare Technology CEO by Healthcare Technology Report

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a commercial-stage, multi-product medical device company, today announced that Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer and Executive Chairman of its...

Apr 08, 2021 09:30 am ET

PAVmed to Present at the 20th Annual Needham Healthcare Conference

Mar 10, 2021 09:30 am ET

PAVmed to Participate in M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference

Mar 03, 2021 09:30 am ET

PAVmed Retires Convertible Debt

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced that it has retired all of the Company’s outstanding convertible debt, applying...

Mar 01, 2021 09:30 am ET

PAVmed Chairman and Chief Executive Officer Lishan Aklog, M.D., Elected to AdvaMed Board of Directors

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that the Advanced Medical Technology Association (AdvaMed), the world’s leading...

Feb 25, 2021 12:37 pm ET

PAVmed Announces Closing of its Public Offering of Common Stock

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced the closing of its previously announced underwritten public offering (the “Offering”) of...

Feb 23, 2021 09:00 am ET

PAVmed Announces Pricing of $45 Million Public Offering of Common Stock

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced the pricing of its previously announced underwritten public offering (the “Offering”) of...

Feb 22, 2021 04:13 pm ET

PAVmed Announces Proposed Public Offering of Common Stock

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced that it is commencing an underwritten public offering of its common stock (the...

Feb 22, 2021 08:18 am ET

PAVmed Provides Business Update and Preliminary Fourth Quarter 2020 Financial Results

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (“Lucid”)...

Feb 18, 2021 09:30 am ET

PAVmed Reschedules Business Update Conference Call on February 22, 2021 to 8:30 AM EST

Feb 16, 2021 09:30 am ET

First U.S. Patient Undergoes Successful Minimally Invasive Carpal Tunnel Release Using PAVmed’s CarpX® Device

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that the first U.S. patient recently underwent successful carpal tunnel release...

Feb 09, 2021 09:30 am ET

PAVmed to Hold Business Update Conference Call on February 22, 2021

Jan 08, 2021 10:53 am ET

PAVmed Closes $13.4 Million Common Stock Registered Direct Offering Priced At-the-Market under Nasdaq Rules

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced the closing of its previously announced registered direct offering (the “Offering”) of...

Jan 06, 2021 09:29 am ET

PAVmed Announces Registered Direct Offering of its Common Stock Priced At-the-Market under Nasdaq Rules

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced it has entered into agreements for the sale of 6.0 million shares of common stock at a...

Dec 22, 2020 12:04 pm ET

PAVmed Closes Additional $8.1 Million Common Stock Registered Direct Offering

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced the closing of its previously announced registered direct offering (the “Offering”) of...

Dec 18, 2020 09:29 am ET

PAVmed Announces Pricing of Additional $8.1 Million Common Stock Registered Direct Offering

Dec 11, 2020 09:29 am ET

PAVmed Announces Registered Direct Offering of its Common Stock

Nov 17, 2020 04:00 pm ET

PAVmed Reports Third Quarter 2020 Financial Results and Provides Business Update

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (“Lucid”)...

Nov 02, 2020 09:30 am ET

PAVmed to Hold Business Update Conference Call on November 17, 2020

Sep 08, 2020 09:30 am ET

PAVmed to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference on September 15, 2020

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced that Lishan Aklog, M.D., Chairman and Chief Executive Officer of the Company, will...

Aug 27, 2020 09:30 am ET

PAVmed to Present at The LD 500 Virtual Conference

NEW YORK, NY / ACCESSWIRE / August 27, 2020 / PAVmed Inc. (NASDAQ:PAVM)(NASDAQ:PAVMZ) (the "Company" or "PAVmed"), a highly differentiated, multi-product, commercial-stage medical device company, today announced that it will be presenting at the LD 500 investor conference on Thursday, September 3, 2020 at 7:20 a.m. PST / 10:20 a.m. EST. Lishan Aklog, M.D., Chairman and Chief Executive Officer of the Company, will be presenting a corporate overview to a live audience.

Aug 18, 2020 04:14 pm ET

PAVmed Reports Second Quarter 2020 Financial Results and Provides Business Update

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today reported financial results for the three and six months ended June 30, 2020 and provided a...

Aug 06, 2020 09:27 am ET

PAVmed Secures $7 Million Convertible Note Financing

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced it has received approximately $7 million in gross proceeds from a private placement (the...

Jul 28, 2020 09:30 am ET

PAVmed to Hold Business Update Conference Call on August 18, 2020

Jul 13, 2020 09:30 am ET

PAVmed to Present at Maxim Group’s COVID-19 Webinar on July 16, 2020

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced that Shaun O’Neil, Chief Commercial Officer of the Company, will participate in a panel...

Jun 17, 2020 09:30 am ET

PAVmed to Join the Russell 2000® and Russell 3000® Indexes

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced the Company is set to join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index as...

Jun 15, 2020 09:30 am ET

Founder and Former Chairman & CEO of Exact Sciences Stanley Lapidus Joins PAVmed Subsidiary Lucid Diagnostics as Strategic Advisor

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that medical diagnostics pioneer Stanley Lapidus, founder and former Chairman and CEO of Exact Sciences...

Jun 11, 2020 09:30 am ET

PAVmed Subsidiary Lucid Diagnostics Receives Preliminary Payment Determination for EsoGuard™ Esophageal DNA Test

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that its majority owned subsidiary, Lucid Diagnostics Inc. (“Lucid”), received preliminary gapfill payment...

Jun 03, 2020 09:30 am ET

PAVmed Collaborates with Canon on DisappEAR™ Pediatric Ear Tubes

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced the Company and global manufacturer Canon Inc.’s United States manufacturing and technology center, Canon...

May 21, 2020 04:00 pm ET

PAVmed Reports Preliminary First Quarter 2020 Financial Results and Provides Business Update

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today reported preliminary financial results for the three months ended March 31, 2020 and provided a business update....

May 11, 2020 09:30 am ET

PAVmed to Hold Business Update Conference Call on May 21, 2020

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the Company will host a business update conference call on Thursday, May 21, 2020 at 4:30 p.m. Eastern...

Apr 21, 2020 09:30 am ET

PAVmed Receives FDA 510(k) Clearance for its CarpX™ Minimally Invasive Carpal Tunnel Device

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced it has received 510(k) marketing clearance from the U.S. Food and Drug Administration (FDA) for its CarpX™...

Apr 09, 2020 04:44 pm ET

PAVmed Reports Preliminary Fourth Quarter 2019 Financial Results and Provides Business Update

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today reported preliminary financial results for the three and 12 months ended December 31, 2019 and provided a business...

Apr 02, 2020 09:30 am ET

PAVmed Subsidiary Lucid Diagnostics’ EsoCheck Esophageal Cell Collection Device Receives Prestigious Edison Best New Product Award

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the EsoCheck™ Esophageal Cell Collection Device with Collect+Protect™ Technology, developed and...

Mar 31, 2020 09:30 am ET

PAVmed Receives $6.3 Million in Gross Proceeds from Completion of November 2019 Financing

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced it has received $6.3 million in new gross proceeds from the prepayment of promissory notes issued in...

Mar 24, 2020 09:30 am ET

PAVmed to Hold Business Update Conference Call on April 9, 2020

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the Company will report fourth quarter 2019 financial results after the market close on Thursday,...

Mar 09, 2020 09:30 am ET

PAVmed Announces FDA 510(k) Re-submission for its CarpX™ Minimally Invasive Carpal Tunnel Device

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced the U.S. Food and Drug Administration (FDA) has acknowledged receipt of a 510(k) premarket notification...

Mar 02, 2020 09:30 am ET

PAVmed Subsidiary Lucid Diagnostics Partners with University of Pennsylvania to Evaluate EsoCheck™ in Eosinophilic Esophagitis (EoE) Patients

Feb 20, 2020 09:30 am ET

PAVmed Subsidiary Lucid Diagnostics Partners with Fred Hutchinson Cancer Research Center to Evaluate Barrett’s Esophagus (BE) Progression Biomarkers Using EsoCheck™

Feb 18, 2020 09:30 am ET

PAVmed Adds EsoCure™ Esophageal Ablation Device with Patented Caldus™ Technology to Commercial Product Pipeline

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced it has added the EsoCure™ Esophageal Ablation Device with Caldus™ Technology to its commercial product...

Feb 11, 2020 09:30 am ET

U.S. FDA Grants PAVmed Subsidiary, Lucid Diagnostics, Breakthrough Device Designation for its EsoGuard Esophageal DNA Test

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the Company’s majority owned subsidiary, Lucid Diagnostics Inc. (“Lucid”), has received Breakthrough...

Jan 13, 2020 09:30 am ET

PAVmed Receives Formal Notification of Nasdaq Continued Listing Compliance

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced it has received formal notification from the Nasdaq Stock Market LLC (“Nasdaq”) of compliance with Nasdaq...

Dec 19, 2019 09:30 am ET

PAVmed Subsidiary Lucid Diagnostics Announces Commercial Launch of EsoGuard Esophageal DNA Test

Dec 13, 2019 09:30 am ET

PAVmed Provides Update on CarpX™ Clinical Safety Study

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today provided an update on its CarpX™ first-in-human (FIH) 510(k) clinical safety study. This week, senior PAVmed...

Nov 21, 2019 04:00 pm ET

PAVmed Reports Third Quarter 2019 Financial Results and Provides Business Update

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today reported financial results for the three and nine months ended September 30, 2019 and provided a business update....

Nov 14, 2019 09:30 am ET

PAVmed Partners with Laser Technology Pioneer Dr. Jacob Wong to Develop and Commercialize Non-Invasive Laser-based Diagnostic Products

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced the Company and its newly formed subsidiary, Solys Diagnostics Inc. (“Solys”), have entered into definitive...

Nov 07, 2019 09:30 am ET

PAVmed’s PortIO™ Intraosseous Infusion System Achieves Multiple Milestones

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that its groundbreaking PortIO™ Intraosseous Infusion System has achieved multiple important development,...

Nov 06, 2019 09:30 am ET

PAVmed to Hold Business Update Conference Call on November 21, 2019

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the Company will file its SEC 10-Q quarterly report on or before the November 14, 2019 deadline,...

Nov 05, 2019 07:00 am ET

PAVmed Secures Financing up to $14 Million for Advancement of its Lead Products to Commercialization

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced it has entered into a financing agreement (the “Financing”) with an existing and a new institutional...

Sep 05, 2019 09:30 am ET

PAVmed Reports Second Quarter 2019 Financial Results and Provides Business Update

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today reported financial results for the three and six months ended June 30, 2019 and provided a business update. “The...

Aug 21, 2019 09:30 am ET

USPTO Grants PAVmed Patent Covering its CarpX™ Device

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent 10,335,189 which covers the...

Aug 15, 2019 09:30 am ET

PAVmed Successfully Completes Clinical Safety Study Procedures for CarpX™ 510(k) Re-submission

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that all 20 patients of its first-in-human (FIH) 510(k) clinical safety study underwent successful CarpX...

Aug 07, 2019 09:30 am ET

PAVmed to Hold Business Update Conference Call on September 5, 2019

Jun 26, 2019 09:30 am ET

PAVmed to Join Russell Microcap® Index

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced the Company is set to join the Russell Microcap® Index at the conclusion of the 2019 Russell indexes annual...

Jun 24, 2019 10:46 am ET

PAVmed Subsidiary Lucid Diagnostics Receives FDA 510(k) Clearance for EsoCheck™

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product medical device company, today announced that its majority owned subsidiary, Lucid Diagnostics Inc. (“Lucid”), has received 510(k) marketing...

May 21, 2019 09:30 am ET

PAVmed Reports First Quarter 2019 Financial Results and Provides Business Update

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today reported financial results for the three months ended March 31, 2019 and provided a business update. MANAGEMENT...

May 20, 2019 09:30 am ET

PAVmed Announces First Human CarpX™ Procedures

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the first group of nine patients with carpal tunnel syndrome underwent successful CarpX procedures as...

May 06, 2019 09:30 am ET

PAVmed to Hold Business Update Conference Call on May 21, 2019

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the Company will report first quarter 2019 financial results on or before May 21, 2019 and host a...

Apr 24, 2019 09:30 am ET

PAVmed Reports Excellent DisappEAR™ Animal Study Results

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that its DisappEAR™ resorbable pediatric ear tube achieved a major developmental milestone with the...

Apr 12, 2019 09:35 am ET

PAVmed Announces Registered Direct Offering of its Common Stock

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced it has entered into agreements for the sale of 1,655,000 shares of common stock in a registered direct...

Apr 04, 2019 09:30 am ET

PAVmed Reports Fourth Quarter 2018 Financial Results and Provides Business Update

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today reported financial results for the three and 12 months ended December 31, 2018 and provided a business update....

Mar 21, 2019 07:30 am ET

PAVmed to Hold Business Update Conference Call on April 4, 2019

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the Company will report fourth quarter 2018 financial results on or before April 4, 2019 and host a...

Mar 20, 2019 07:30 am ET

PAVmed Announces NextFlo™ Breakthrough

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that its NextFlo™ Infusion System (“NextFlo”) achieved a key milestone in its quest to eliminate the need...

Mar 13, 2019 08:04 am ET

PAVmed Announces PortIO™ Breakthrough

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that its PortIO™ Intraosseous Infusion System, which consists of an implantable intraosseous vascular...

Feb 28, 2019 12:49 pm ET

PAVmed Subsidiary Lucid Diagnostics Launches World-Class Medical Advisory Board and Appoints Chief Medical Officer

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product medical device company, today announced that its subsidiary, Lucid Diagnostics Inc. (“Lucid”), has launched a world-class medical advisory board...

Feb 26, 2019 07:30 am ET

PAVmed Provides Business Update

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today provided an update on its business. “I am pleased to report that PAVmed’s 2019 is off to an excellent start with...

Jul 11, 2018 07:30 am ET

PAVmed Names Shaun O’Neil Chief Commercial Officer

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that it has named Shaun M. O’Neil to serve as its first Chief Commercial Officer. Mr. O’Neil will oversee all aspects of the domestic and international commercialization of PAVmed’s products including sales and marketing, clinician engagement and professional education. He will officially assume his role on July 23 reporting directly to Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Office

Jul 09, 2018 07:30 am ET

Nasdaq Notifies PAVmed of Regained Compliance with Continued Listing Requirements

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that The Nasdaq Stock Market LLC (“Nasdaq”) has notified the Company that it has regained compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(b)(1).

Jun 27, 2018 08:30 am ET

PAVmed Provides Business Update

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today provided a business update following its recently closed, oversubscribed rights offering.

Jun 13, 2018 05:34 pm ET

Dawson James Securities Announces the Closing of Oversubscribed $10,350,000 Rights Offering for PAVmed, Inc.

Dawson James Securities, Inc. and Maxim Group LLC acted as dealer-managers on an oversubscribed equity subscription rights offering for PAVmed Inc. (Nasdaq:PAVM) (Nasdaq:PAVMZ) which raised the maximum gross proceeds of $10,350,000 and closed on...

Jun 12, 2018 04:05 pm ET

PAVmed Closes Oversubscribed Rights Offering for Gross Proceeds of $10,350,000

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced the closing of its oversubscribed equity subscription rights offering (the “Rights Offering”), which raised the maximum gross proceeds of $10,350,000.

Jun 08, 2018 07:30 am ET

PAVmed to Receive $10.4 Million in Gross Proceeds from Oversubscribed Rights Offering

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced its previously announced equity subscription rights offering (the “Rights Offering”) expired at 5:00 p.m. Eastern Time on Thursday, June 7, 2018 and, as such, the rights are no longer exercisable. The Company received subscriptions that exceeded the number of rights available to be exercised under the Rights Offering and has accepted all valid subscriptions including up to 9 million units of the tota

Jun 01, 2018 07:30 am ET

PAVmed Updates the Terms of Previously Announced Rights Offering

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company”), a highly differentiated, multiproduct medical device company, today announced that its board of directors has approved the following changes to its previously announced rights offering: (i) the common stock and Series Z Warrants included in the units will now be tradeable immediately upon their issuance, and (ii) the subscription price shall be $1.15 per unit. Each right now entitles the holder to purchase one unit at the subscription price of $1.15 per unit and each unit remains comprise

May 23, 2018 07:30 am ET

PAVmed Updates Expected Key Dates for Previously Announced Rights Offering

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company”), a highly differentiated, multiproduct medical device company, previously announced on May 8, 2018 that the Company had filed a preliminary prospectus as part of a registration statement on Form S-1 with the Securities and Exchange Commission for a rights offering (the “Rights Offering”) to stockholders of record on Monday, May 21, 2018.

May 22, 2018 07:30 am ET

PAVmed Reports First Quarter 2018 Financial Results

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today reports financial results for the three months ended March 31, 2018 and provides a business update.

May 18, 2018 07:30 am ET

PAVmed Inc. to Hold Business Update Conference Call on May 30, 2018

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company”), a highly differentiated, multiproduct medical device company, today announced that the Company will host a conference call on Wednesday, May 30, 2018 at 4:30 p.m. Eastern time. During the call, Lishan Aklog, M.D., Chairman and Chief Executive Officer of the Company, will provide a business update including an overview of the Company’s near-term milestones and growth strategy. In addition, Dennis McGrath, the Company’s Chief Financial Officer, will discuss first quarter 2018 financial resu

May 15, 2018 07:30 am ET

PAVmed Announces Adjustment to Series Z Warrant Exercise Price

PAVmed Inc. (Nasdaq: PAVM, PAVMW)) (“PAVmed”), a highly differentiated, multiproduct medical device company, announced today that its board of directors approved a reduction to the exercise price of its Series Z Warrants (CUSIP number 70387R122) (the “Series Z Warrants”) that trade under the symbol “PAVMZ” on the Nasdaq Capital Market from $3.00 per share to $1.60 per share. Before this reduction takes effect, notice must first be provided to the current holders of Series Z Warrants. The effective date of the exercise price reduction

May 14, 2018 07:30 am ET

PAVmed and Case Western Reserve University Finalize Definitive Licensing Agreement for Groundbreaking EsoCheck Technology

PAVmed Inc. (Nasdaq:PAVM, PAVMZ), a highly differentiated, multi-product medical device company, today announced it has finalized a definitive licensing agreement with Case Western Reserve University to develop and commercialize its groundbreaking EsoCheck technology.

May 08, 2018 07:30 am ET

PAVmed Sets Record Date for Previously Announced Rights Offering

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company”), a highly differentiated, multiproduct medical device company, today announced that the Company has filed a preliminary prospectus as part of a registration statement on Form S-1 with the Securities and Exchange Commission for a rights offering (the “Rights Offering”) to stockholders of record on Monday, May 21, 2018.

Apr 24, 2018 07:30 am ET

PAVmed Signs Letter of Intent with Case Western Reserve University to Commercialize Groundbreaking EsoCheck Technology

PAVmed Inc. (Nasdaq: PAVM, PAVMZ), a highly differentiated, multi-product medical device company, today announced that it has signed a letter of intent with Case Western Reserve University to commercialize its groundbreaking EsoCheck technology.

Apr 11, 2018 07:30 am ET

PAVmed Reports Fourth Quarter and Full Year 2017 Financial Results

PAVmed Inc. (Nasdaq:PAVM, PAVMZ) (the “Company”), a highly differentiated, multiproduct medical device company, today reports financial results for the three and 12 months ended December 31, 2017 and provides a business update.

Ad blocking detected

PAVmed Inc. - Series Z Warrant (OQ:PAVMZ)

Business Focus: N/A